Toilet Papering Was a Prank. Premiumization Is the Strategy.

There's a decades-old American tradition where kids unroll toilet paper over trees at night. A New Jersey family has done it to their own house for 31 years — about 200 rolls a pop, starting cleanup at dawn. On TikTok, it's still framed as "nostalgic childhood fun."

The thing that strikes me is what these kids learned instinctively about toilet paper: it's cheap enough to waste, ubiquitous enough to grab, and disposable enough to leave behind. That instinct is exactly the problem for the companies that sell it.

Kimberly-Clark, the world's largest tissue maker, is trying to do the opposite. It wants you to believe toilet paper is worth upgrading.

The global toilet paper market is valued at USD 61.33 Billion in 2026 and projected to grow to USD 83.00 billion by 2035, according to one estimate. Another puts the growth path at USD 61.04 billion by 2034. Both models expect compound annual growth in the low-to-mid single digits.

The industry's growth engine is premiumization. In North America and Europe, consumers are trading up from two-ply to three- and four-ply products. Premium SKUs command a 35% to 50% price premium per roll. In emerging markets like India, per-capita tissue spending is under $1.50 annually versus $35 in the U.S., leaving enormous runway for value-per-unit growth.

On the surface, this is a textbook consumer story. People buy nicer versions of everyday products. Revenue grows without volume growth. Margins expand. It's what P&G does with Charmin, what Coca-Cola does with premium variants, what every company in slow-growth categories does.

But there's a contradiction at the center of it.

The very generational shift that's supposed to carry premiumization is also the one most willing to abandon national brands. Gen Z and Millennials now drive private label spending at rates that are projected to surpass Baby Boomers. Forty-six percent of Gen Z and 50% of Millennials believe store brands offer better value than name brands. They're not just buying cheaper private label — they're trading up within private label tiers, narrowing the quality gap that used to protect the incumbents.

In several European markets, private-label share surpassed 56% by 2024. In the U.S., Costco's Kirkland Signature and Charmin together account for more than 30% of retail volume. The price gap between private label and national brands has widened by 38% since 2019. And once consumers switch, they tend to stay.

Nearly half of global shoppers now predominantly buy private label. The shift is structural, not cyclical. Shoppers are skeptical of premium pricing without tangible proof of value. Brands are being pushed into emotional and indulgent categories where they must work harder to justify the markup.

Now look at what Kimberly-Clark actually reported.

In Q2 2026, net sales were $4.19 billion, a 0.6% increase year-over-year, missing consensus estimates of $4.22 billion. Organic sales growth was flat. Consolidated volume fell 0.1% for the quarter. Net price had a negative impact of 0.5%.

This is what premiumization looks like when the tailwind stalls.

The headline EPS story is rosier: adjusted diluted EPS of $2.12, up 10.4%, beating analyst estimates of $2.01. But that growth came from productivity savings, one-time tariff refunds, and margin expansion (adjusted gross margin up 190 basis points to 38.8%), not from selling more rolls at higher prices. North American organic sales declined 0.7%, weighed down by retail inventory changes and a distribution center fire in Los Angeles. International personal care grew 4.0%, but that segment was hit by a separate headwind — false social media allegations about diaper quality in China, costing roughly 50 basis points of organic sales and 210 basis points of operating profit.

Kimberly-Clark's response to this squeeze is a pivot away from the tissue business itself. The company launched Arbex, a joint venture with Suzano focused on sustainable materials. It announced an alternative natural fibers pilot plant in the Southwest U.S. It's spending $109 million in Q2 alone on the pending acquisition of Kenvue — the consumer health spinoff from Johnson & Johnson — expected to close by year-end. CEO Mike Hsu calls it a "new kind of health and wellness company."

The way to grow isn't to sell better toilet paper. It's to become a company that does other things alongside toilet paper.

That's not cynical. It's honest. When volumes are flat and private label is eating the mid-tier, premiumization works until it doesn't. Multi-ply and infused variants (aloe, vitamin E) are the high-margin frontier. But so is bamboo fiber, which is growing at a 5.34% CAGR, eating into the recycled-fiber base that held 49.5% market share in 2025. The EU's Ecolabel mandate, effective mid-2024, requires 70% certified-sustainable fiber. Regulatory moves and material innovation are creating new entry points for competitors who don't have Kimberly-Clark's legacy cost structure.

Meanwhile, bidet adoption in Japan exceeds 80% of homes. In South Korea and parts of Europe, it reduces toilet paper usage per household by 50% to 75%. That's a long-term structural headwind for volumes that won't show up in quarterly earnings but is already baked into the category's ceiling.

So what's the real question here?

It's not whether Kimberly-Clark can engineer another margin point or launch another premium SKU. It's whether a $61 billion market built on a product that children learn to treat as disposable waste can sustain the premiumization strategy that the incumbents are counting on.

I suspect the premiumization playbook works for a while — maybe another two to three years — because consumer habits are slow and the trade-up from two-ply to three-ply is still incomplete in many households. But the generational handoff is real. The parents who grew up toilet-papering houses are the ones now buying Charmin and Scott at full price. Their kids have never needed brand loyalty to find what they want. They'll buy the Kirkland Signature equivalent because the quality gap has closed, the packaging looks fine, and the savings compound across every trip to the grocery store.

The test is simple. Watch private-label premium tiers in tissue over the next four quarters. If they're gaining share at the expense of national brands' mid-tier and premium SKUs — not just their value tier — the premiumization story is ending earlier than Kimberly-Clark's guidance assumes. If private label stays in the value lane and national brands keep pulling premium share, the model holds for now.

Either way, the company buying Kenvue is already voting on its own answer: tissue is no longer the growth engine. The question is whether the market will keep paying for it as if it is.